Fundamental Analysis of Talaris Therapeutics Inc - Growth / Value Index


TALS - Valuation Highlights

Valuation Analysis

   Price to Book Ratio is 0.532 indicating that it is undervalued.
   Tsr Value Index - Very Poor Score of 14.29
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -0.903 -1.52 -25.99 %
Price to Book 0.532 0.623 162.47 % 0.081
Price to Sales 0 0 0 %
Enterprise Value to EBITDA Multiple -0.991 -1.34 -62.96 %


TALS - Profitability Highlights

Profitability Analysis

   Gives Dividend Yield of 503933 %
   Excellent QoQ /QoQ FY EPS growth
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 1.0
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -58.91 -41.04 -108.32 % -4.91
Return On Asset -55.24 -38.15 -100.50 % -4.64
Net Profit Margin 0 0 0 % 0
Operating Profit Margin 0 0 0 % 0
EBITDA Margin 0 0 0 % 0


Highlights
Market Cap116444 K
Enterprise Value103684 K
Price/Book TTM0.532
Outstanding Share42810.60 K
Float/ Outstanding Share9.83%
Dividend Yield503933 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score1.00
Altman Z Score3.70
Sloan Ratio-0.067
Peter Lynch Fair Value0


TALS - Growth Highlights

Growth Analysis

   Quarterly sales in last 5 years is trending up
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue NA % %
Gross Profit NA % %
EBITDA -104574.00 K 56.33 % 45.87 %
Net Profit -97552.00 K 54.48 % 52.40 %
EPS -3.01 20.63 % NA


TALS - Stability Highlights

Stability Analysis

   Altman Z Score of 3.70 suggests good Stability
   Cash ratio of 15.82
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -29.61
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0051 0 % 0.0044
Cash Ratio 15.82 -48.22 %
Quick Ratio 0 0 % 18.64
Shareholders Equity 92.95 -3.75 %
Debt to EBITDA -0.0122 0 %


Historical Valuation Ratios of Talaris Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Talaris Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Talaris Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Talaris Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)